Stock OCGN OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ocugen, Inc.

Equities

OCGN

US67577C1053

Real-time Estimate Cboe BZX
Other stock markets
 10:51:30 2024-05-20 am EDT 		5-day change 1st Jan Change
1.915 USD +0.26% Intraday chart for Ocugen, Inc. +6.08% +233.91%
May. 15 Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study MT
May. 15 Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for Ocu400?Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial
Sector Update: Health Care Stocks Rise Late Afternoon
Sector Update: Health Care Stocks Rise Friday Afternoon
Ocugen Says Data, Safety Monitoring Board Issues 'Positive' Review of Eye Disease Treatment -- Shares Rise
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Ocugen to Restate Financial Statements; Shares Tumble
Ocugen Provides Business Update
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410st?A Modifier Gene Therapy?In Gardian Study for Stargardt Disease
Sector Update: Health Care Stocks Steady Premarket Monday
Sector Update: Health Care Stocks Ease Late Afternoon
Ocugen Stock Rallies After Appeals Court Dismisses Allegations of Misleading Shareholders
Ocugen, Inc. Announces Ramesh Kumar Will Not Stand for Re-Election as Director
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. News Ocugen, Inc.
  5. Other languages
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW